Template:Cyproterone acetate levels with oral and intramuscular cyproterone acetate

From blackwiki
Jump to navigation Jump to search
Template documentation

See also

References

  1. Kuhnz W, Kulmann H, Fuhrmeister A (1997). "Investigation into the age-dependence of the pharmacokinetics of cyproterone acetate in healthy male volunteers". Eur. J. Clin. Pharmacol. 53 (1): 75–80. doi:10.1007/s002280050340. PMID 9349934.
  2. 2.0 2.1 2.2 2.3 Neumann, F; Hümpel, M; Senge, Th; Schenck, B; Tunn, U (1 December 1982). "Cyproterone Acetate—Biochemical and Biological Basis for Treatment of Prostatic Cancer". In Jacobi, Günther H; Hohenfellner, Rudolf (eds.). Prostate Cancer. Williams & Wilkins. pp. 269–303. ISBN 978-0-683-04354-9.
  3. 3.0 3.1 Neumann F, Wiechert R (March 1988). "Das Antiandrogen Cyproteronacetat Seine Geschichte von der Entdeckung bis zur Marktreife" [The antiandrogen cyproterone acetate. Its history from discovery to marketing]. Pharmazie in unserer Zeit (in German). 17 (2): 33–50. doi:10.1002/pauz.19880170202. ISSN 0048-3664. PMID 2967500.
  4. 4.0 4.1 Hammerstein J, Moltz L, Schwartz U (July 1983). "Antiandrogens in the treatment of acne and hirsutism". J. Steroid Biochem. 19 (1B): 591–7. doi:10.1016/0022-4731(83)90223-6. PMID 6224974.
  5. 5.0 5.1 Hammerstein, J. (1990). "Antiandrogens: Clinical Aspects". Hair and Hair Diseases. pp. 827–886. doi:10.1007/978-3-642-74612-3_35. ISBN 978-3-642-74614-7.
  6. 6.0 6.1 Rost A, Schmidt-Gollwitzer M, Hantelmann W, Brosig W (1981). "Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer". The Prostate. 2 (3): 315–22. doi:10.1002/pros.2990020310. PMID 6458025.